
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc has demonstrated strong financial momentum, with the Integrity product line projecting over 100% revenue growth in 2025 compared to 2024, indicating robust market acceptance and demand. Additionally, the company reported a 41% growth in its regenerative solutions segment, largely attributed to the success of the Integrity patch. Furthermore, international revenue from osteoarthritis pain management increased by 21% year-over-year, reinforcing the company's expanding footprint and sales effectiveness in global markets.
Bears say
Anika Therapeutics experienced a revenue decline of approximately 5.9% to $27.8 million, and an 8.2% decrease to $28.2 million in subsequent periods, indicating ongoing challenges in its top-line growth. Additionally, the company reported a disappointing gross margin of 56%, lower than the estimated 58%, primarily attributed to production yield issues, which further compound its financial difficulties. Furthermore, the international revenue from osteoarthritis pain management dropped by 10% year-over-year, suggesting persistent issues with order timing and production that may hinder future performance.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares